Viscosupplementation – Current and Future Players

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. Growth of the viscosupplementation market will be highest in the US and the Asia-Pacific (APAC) region, where there is a significant pent-up demand for early intervention in the management of OA. The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids. *This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.

Scope

N/A

Reasons to buy

N/A

Table of Contents

1Table of Contents

1.1List of Tables

2Introduction

2.1Catalyst

2.2Related Reports

3Treatment Modalities Overview

3.1Treatment Paradigm

3.1.1Physical Therapies

3.1.2Medications

3.1.3Hyaluronic Acid Viscosupplementation

3.1.4Surgical Intervention

4Competitive Assessment

4.1Major Viscosupplementation Products

4.1.1Adant

4.1.2Arthrum

4.1.3Curavisc

4.1.4Durolane

4.1.5Euflexxa

4.1.6Fermathron

4.1.7Gel-One

4.1.8Go-On

4.1.9Hyalgan

4.1.10Hyalubrix and HyalOne

4.1.11Jonexa

4.1.12NeoVisc

4.1.13Orthovisc and Monovisc

4.1.14Ostenil

4.1.15Recosyn

4.1.16RenehaVis

4.1.17Supartz/ARTZ

4.1.18Suplasyn

4.1.19Suvenyl

4.1.20Synocrom

4.1.21Synolis V-A

4.1.22Synovial

4.1.23Synvisc and Synvisc-One

4.2Other Viscosupplementation Products

5Pipeline Products

5.1Overview

5.2Gel-Syn (IBSA Institut Biochimique S.A.)

5.3Cingal (Anika Therapeutics)

5.4Hydros-TA (Carbylan Therapeutics)

5.5Additional Indication for Synvisc-One (Sanofi)

5.6Hymovis (Fidia Farmaceutici S.p.A.)

5.7HA-NSAID Conjugates (Seikagaku Corporation)

5.8Additional Indication for Supartz/ARTZ (Seikagaku Corporation)

5.9Clodronate-HA Conjugates (Abiogen Pharma)

6Current and Future Players

6.1Trends in Corporate Strategy

6.2Major Manufacturers

6.2.1Anika Therapeutics

6.2.2Chugai Pharmaceutical

6.2.3Ferring Pharmaceuticals

6.2.4Fidia Farmaceutici S.p.A.

6.2.5Meda AB

6.2.6Sanofi

6.2.7Seikagaku Corporation

6.3Major Marketing Partners

6.3.1Bioventus

6.3.2DePuy Synthes

6.3.3Zimmer-Biomet

7Appendix

7.1Bibliography

7.2Abbreviations

7.3Report Methodology

7.3.1Overview

7.3.2Coverage

7.3.3Secondary Research

7.3.4Forecasting Methodology

7.3.5Primary Research — Key Opinion Leader Interviews

7.3.6Expert Panel Validation

7.4Physicians and Specialists Included in This Study

7.5About the Authors

7.5.1Analysts

7.5.2Jim Coutcher, MS, Global Head of Healthcare

7.6About MediPoint

7.7About GlobalData

7.8Contact Us

7.9Disclaimer

List of Tables

Table 1: Product Profile – Adant

Table 2: Product Profile – Arthrum

Table 3: Product Profile – Curavisc

Table 4: Product Profile – Durolane

Table 5: Product Profile – Euflexxa

Table 6: Product Profile – Fermathron

Table 7: Product Profile – Gel-One

Table 8: Product Profile – Go-On

Table 9: Product Profile – Hyalgan

Table 10: Product Profile – Hyalubrix and HyalOne

Table 11: Product Profile – Jonexa

Table 12: Product Profile – NeoVisc

Table 13: Product Profile – Orthovisc and Monovisc

Table 14: Product Profile – Ostenil

Table 15: Product Profile – Recosyn

Table 16: Product Profile – RenehaVis

Table 17: Product Profile – Supartz/ARTZ

Table 18: Product Profile – Suplasyn

Table 19: Product Profile – Suvenyl

Table 20: Product Profile – Synocrom

Table 21: Product Profile – Synolis V-A

Table 22: Product Profile – Synovial

Table 23: Product Profile – Synvisc and Synvisc-One

Table 24: Other Viscosupplementation Products in the Global Market, 2015

Table 25: Major Pipeline Products in the Viscosupplementation Market, 2015

Table 26: Company Profile – Anika Therapeutics

Table 27: Anika Therapeutics’ Viscosupplementation Portfolio Assessment, 2015

Table 28: SWOT Analysis – Anika Therapeutics

Table 29: Company Profile – Chugai Pharmaceutical

Table 30: Chugai Pharmaceutical’s Viscosupplementation Portfolio Assessment, 2015

Table 31: SWOT Analysis – Chugai Pharmaceutical

Table 32: Company Profile – Ferring Pharmaceuticals

Table 33: Ferring Pharmaceutical’s Viscosupplementation Portfolio Assessment, 2015

Table 34: SWOT Analysis – Ferring Pharmaceuticals

Table 35: Company Profile – Fidia Farmaceutici S.p.A.

Table 36: Fidia Farmaceutici S.p.A.’s Viscosupplementation Portfolio Assessment, 2015

Table 37: SWOT Analysis – Fidia Farmaceutici S.p.A.

Table 38: Company Profile – Meda AB

Table 39: Meda AB’s Viscosupplementation Portfolio Assessment, 2015

Table 40: SWOT Analysis – Meda AB

Table 41: Company Profile – Sanofi

Table 42: Sanofi’s Viscosupplementation Portfolio Assessment, 2015

Table 43: SWOT Analysis – Sanofi

Table 44: Company Profile – Seikagaku Corporation

Table 45: Seikagaku Corporation’s Viscosupplementation Portfolio Assessment, 2015

Table 46: SWOT Analysis – Seikagaku Corporation

Table 47: Company Profile – Bioventus

Table 48: Bioventus’ Viscosupplementation Portfolio Assessment, 2015

Table 49: SWOT Analysis – Bioventus

Table 50: Company Profile – DePuy Synthes

Table 51: DePuy Synthes’ Viscosupplementation Portfolio Assessment, 2015

Table 52: SWOT Analysis – DePuy Synthes

Table 53: Company Profile – Zimmer-Biomet

Table 54: Zimmer-Biomet’s Viscosupplementation Portfolio Assessment, 2015

Table 55: SWOT Analysis – Zimmer-Biomet

List of Figures

N/A

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports